High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2α

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 18-31

  Kim, Ran Ju ^a,b   Park, Jeong Ran ^a   Roh, Kyung Jin ^a   Choi, A Ram ^a   Kim, Soo Rim ^a   Kim, Pyeung Hyeun ^b   Yu, Jong Han ^c   Lee, Jong Won ^c   Ahn, Sei Hyun ^c   Gong, Gyungyub ^c   Hwang, Jae Woong ^d   Kang, Kyung Sun ^d   Kong, Gu ^e   Sheen, Yhun Yhong ^f   Nam, Jeong Seok ^a  

^a Gachon University College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Hanyang University   (South Korea)

^f Ewha Womans University   (South Korea)

Author keywords

Aldehyde dehydrogenase; Breast cancer; Cancer stem cell; Hypoxia inducible factor 2

Indexed keywords

ALDEHYDE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OCTAMER TRANSCRIPTION FACTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER STEM CELL; CELL HYPOXIA; CELL POPULATION; CELL RENEWAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALDEHYDE DEHYDROGENASE; ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3;

MUS;

EID: 84876086500     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.026     Document Type: Article

References (62)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Moody S.E., Perez D., Pan T.-C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
3. Cil T., Fishell E., Hanna W., Sun P., Rawlinson E., Narod S.A., McCready D.R. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 2009, 115:5780-5787.
4. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
5. Charafe-Jauffret E., Monville F., Ginestier C., Dontu G., Birnbaum D., Wicha M.S. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008, 75:75-84.
6. Gangemi R., Paleari L., Orengo A.M., Cesario A., Chessa L., Ferrini S., Russo P. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem. 2009, 16:1688-1703.
7. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
8. Vasiliou V., Pappa A., Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab. Rev. 2004, 36:279-299.
9. Morimoto K., Kim S.J., Tanei T., Shimazu K., Tanji Y., Taguchi T., Tamaki Y., Terada N., Noguchi S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009, 100:1062-1068.
10. Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., Helyer L., Pan L., Leidal A., Gujar S., Giacomantonio C.A., Lee P.W. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45.
11. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
12. Croker A.K., Allan A.L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res. Treat. 2012, 133:75-87.
13. Moreb J.S., Baker H.V., Chang L.-J., Amaya M., Lopez M.C., Ostmark B., Chou W. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 2008, 7:87.
14. Chute J.P., Muramoto G.G., Whitesides J., Colvin M., Safi R., Chao N.J., McDonnell D.P. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:11707-11712.
15. Ginestier C., Wicinski J., Cervera N., Monville F., Finetti P., Bertucci F., Wicha M.S., Birnbaum D., Charafe-Jauffret E. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009, 8:3297-3302.
16. Levi B.P., Yilmaz O.H., Duester G., Morrison S.J. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 2009, 113:1670-1680.
17. Tanaka S., Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J. Gastroenterol. 2011, 46:289-296.
18. 2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
19. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
20. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
21. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., Shi Q., Cao Y., Lathia J., McLendon R.E. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
22. Nagano M., Kimura K., Yamashita T., Ohneda K., Nozawa D., Hamada H., Yoshikawa H., Ochiai N., Ohneda O. Hypoxia responsive mesenchymal stem cells derived from human umbilical cord blood are effective for bone repair. Stem Cells Dev. 2010, 19:1195-1210.
23. Vasiliou V., Nebert D.W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum. Genom. 2005, 2:138-143.
24. Nam J.S., Kang M.J., Suchar A.M., Shimamura T., Kohn E.A., Michalowska A.M., Jordan V.C., Hirohashi S., Wakefield L.M. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 2006, 66:7176-7184.
25. Nam J.S., Suchar A.M., Kang M.J., Stuelten C.H., Tang B., Michalowska A.M., Fisher L.W., Fedarko N.S., Jain A., Pinkas J., Lonning S., Wakefield L.M. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res. 2006, 66:6327-6335.
26. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
27. Kim R.J., Kim S.R., Roh K.J., Park S.B., Park J.R., Kang K.S., Kong G., Tang B., Yang Y.A., Kohn E.A., Wakefield L.M., Nam J.S. Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett. 2010, 287:172-181.
28. Schwab L.P., Peacock D.L., Majumdar D., Ingels J.F., Jensen L.C., Smith K.D., Cushing R.C., Seagroves T.N. Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 2012, 14:R6.
29. Chen L., Endler A., Uchida K., Horiguchi S., Morizane Y., Iijima O., Toi M., Shibasaki F. Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2alpha expression. Circulation 2010, 122:910-919.
30. Hess D.A., Wirthlin L., Craft T.P., Herrbrich P.E., Hohm S.A., Lahey R., Eades W.C., Creer M.H., Nolta J.A. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006, 107:2162-2169.
31. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., Wang H., Liu Z., Su Y., Stass S.A., Katz R.L. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009, 7:330-338.
32. Marcato P., Dean C.A., Giacomantonio C.A., Lee P.W. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011, 10:1378-1384.
33. Muzio G., Maggiora M., Paiuzzi E., Oraldi M., Canuto R.A. Aldehyde dehydrogenases and cell proliferation. Free Radical Biol. Med. 2012, 52:735-746.
34. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., Hur M.H., Diebel M.E., Monville F., Dutcher J., Brown M., Viens P., Xerri L., Bertucci F., Stassi G., Dontu G., Birnbaum D., Wicha M.S. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69:1302-1313.
35. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., Houvenaeghel G., Extra J.M., Bertucci F., Jacquemier J., Xerri L., Dontu G., Stassi G., Xiao Y., Barsky S.H., Birnbaum D., Viens P., Wicha M.S. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16:45-55.
36. Su Y., Qiu Q., Zhang X., Jiang Z., Leng Q., Liu Z., Stass S.A., Jiang F. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19:327-337.
37. Aslakson C.J., Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52:1399-1405.
38. Lelekakis M., Moseley J.M., Martin T.J., Hards D., Williams E., Ho P., Lowen D., Javni J., Miller F.R., Slavin J., Anderson R.L. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 1999, 17:163-170.
39. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
40. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4966-4971.
41. Moreb J.S. Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 2008, 3:237-246.
42. Wright M.H., Calcagno A.M., Salcido C.D., Carlson M.D., Ambudkar S.V., Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10:R10.
43. Steiniger S.C., Coppinger J.A., Kruger J.A., Yates J., Janda K.D. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 2008, 26:3037-3046.
44. Vaillant F., Asselin-Labat M.L., Shackleton M., Forrest N.C., Lindeman G.J., Visvader J.E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 2008, 68:7711-7717.
45. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., Samuel S., Kim M.P., Lim S.J., Ellis L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69:1951-1957.
46. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
47. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., Keith B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20:557-570.
48. Liu S., Wicha M.S. Targeting breast cancer stem cells. J. Clin. Oncol. 2010, 28:4006-4012.
49. Heddleston J.M., Li Z., McLendon R.E., Hjelmeland A.B., Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
50. Seidel S., Garvalov B.K., Wirta V., von Stechow L., Schanzer A., Meletis K., Wolter M., Sommerlad D., Henze A.T., Nister M., Reifenberger G., Lundeberg J., Frisen J., Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983-995.
51. Hu T., Liu S., Breiter D.R., Wang F., Tang Y., Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008, 68:6533-6540.
52. Kim R.J., Nam J.S. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab. Anim. Res. 2011, 27:147-152.
53. Choi H., Chun Y.S., Kim T.Y., Park J.W. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res. 2010, 70:10101-10111.
54. Trapani J.A., Sutton V.R. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 2003, 15:533-543.
55. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., Poellinger L., Pahlman S. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10:413-423.
56. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., Armesilla A.L., Xu B., Cassidy J., Darling J.L., Wang W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574.
57. Nobel C.I., Kimland M., Lind B., Orrenius S., Slater A.F. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J. Biol. Chem. 1995, 270:26202-26208.
58. Jin Y., Lu Z., Ding K., Li J., Du X., Chen C., Sun X., Wu Y., Zhou J., Pan J. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010, 70:2516-2527.
59. Rausch V., Liu L., Kallifatidis G., Baumann B., Mattern J., Gladkich J., Wirth T., Schemmer P., Buchler M.W., Zoller M., Salnikov A.V., Herr I. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010, 70:5004-5013.
60. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66:10425-10433.
61. Koh M.Y., Lemos R., Liu X., Powis G. The hypoxia-associated factor switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 2011, 71:4015-4027.
62. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.